Antifibrinolytic therapy: New data and new concepts

The Lancet

Volumn 376, Issue 9734, 2010, Pages 3-4

  Levy, Jerrold H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; PLACEBO; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; UROKINASE;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BLOOD VESSEL OCCLUSION; CYTOKINE RELEASE; ENDOTHELIUM CELL; FIBRINOLYSIS; HEART SURGERY; HEMOSTASIS; HUMAN; INFLAMMATION; INJURY; MONOCYTE; MORTALITY; NEUROTOXICITY; NEUTROPHIL; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SEIZURE; THROMBOCYTE; PHYSIOLOGY;

ANTIFIBRINOLYTIC AGENTS; FIBRINOLYSIN; HEMORRHAGE; HEMOSTASIS; HUMANS; TRANEXAMIC ACID; WOUNDS AND INJURIES;

EID: 77954745372     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60939-7     Document Type: Note

References (12)

1. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-321
2. Chandler WL. The human fibrinolytic system. Crit Rev Oncol Hematol 1996; 24: 27-45.
3. Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost 2007; 5 (suppl 1): 132-142
4. Levy JH, Dutton RP, Hemphill JC 3rd, et al. Multidisciplinary approach to the challenge of hemostasis. Anesth Analg 2010; 110: 354-364
5. Zufferey P, Merquiol F, Laporte S, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 2006; 105: 1034-1046
6. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115: 2801-2813
7. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; published online June 15. DOI:10.1016/S0140-6736(10)60835-60845
8. Dowd NP, Karski JM, Cheng DC, et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 2002; 97: 390-399
9. Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994; 83: 404-414
10. Syrovets T, Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 2004; 61: 873-885
11. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010; 110: 21-29.
12. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008; 107: 1783-1790